Lupin has been granted approval by the USFDA to market Lenalidomide Capsules, a cancer treatment drug, in the US. The drug, a bioequivalent to Revlimid by Bristol-Myers Squibb, will be produced at ...

The announcement comes a day after Lupin said the US FDA had inspected its Nagpur injectable facility between September 8 and ...

Lupin has received USFDA approval to market generic Lenalidomide capsules, a version of Bristol-Myers Squibb's cancer drug Revlimid, which posted $7.5 bn US sales in July 2025 ...

Lupin receives FDA approval for Lenalidomide Capsules, a generic version of Revlimid, for multiple myeloma treatment.

Lupin has bagged the approval for Lenalidomide capsules. This drug is used in the treatment of Multiple Myeloma (MM). In an ...

Revlimid (lenalidomide) is a brand-name drug that doctors may prescribe to treat certain cancers of the blood. If a person has a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) ...

Johnson & Johnson’s (J&J’s) multiple myeloma combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and ...

Starton has been issued multiple U.S. patents covering the continuous delivery of lenalidomide and other immunomodulatory ...

Drug maker Lupin on Wednesday said it has received approval to market a cancer treatment drug in the US market.The company ...